Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific
December 1, 2020
Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.
- Buyers
- Laboratoires SERB, Charterhouse Capital Partners LLP
- Targets
- BTG Specialty Pharmaceuticals
- Sellers
- Boston Scientific
- Platforms
- Laboratoires SERB
- Industry
- Pharmaceuticals
- Location
- Pennsylvania, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Boston Scientific Acquires BTG plc
August 19, 2019
Medical Devices
Boston Scientific Corporation completed its acquisition of BTG plc by scheme of arrangement, with BTG shareholders receiving 840 pence in cash per share. The purchase brings BTG’s interventional medicine portfolio, specialty pharmaceuticals and licensing business into Boston Scientific, strengthening its capabilities in interventional oncology and vascular therapies.
-
SERB Pharmaceuticals Acquires Y-mAbs Therapeutics
September 16, 2025
Biotechnology
SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.
-
Charterhouse Acquires Labomar S.p.A.
September 7, 2023
Pharmaceuticals
Charterhouse Capital Partners has invested in Labomar S.p.A., partnering with founder and CEO Walter Bertin and existing minority shareholder Cleon Capital; Labomar's shares were delisted as part of the transaction. Charterhouse will support Labomar's next phase of growth via a buy-and-build strategy to consolidate fragmented markets and expand the company's CDMO capabilities across food supplements, medical devices and functional cosmetics.
-
CURE Pharmaceutical to Acquire Sera Labs for $20 Million
July 30, 2020
Consumer Products
CURE Pharmaceutical entered a memorandum of understanding to acquire 100% of privately held Sera Labs for $20 million in a deal composed primarily of CURE stock, with potential earn-outs of up to an additional $20 million. The acquisition adds Sera Labs' CBD-focused branded portfolio, DTC subscription model and retail/wholesale distribution (over 8,850 U.S. doors) to CURE's cGMP manufacturing and drug-delivery capabilities, with Sera Labs founder Nancy Duitch remaining in a leadership role.
-
Valtech Acquires The Berndt Group (TBG)
April 7, 2022
Healthcare Services
Valtech, a global business transformation agency, has acquired The Berndt Group (TBG), a Baltimore-based digital customer experience agency focused on digital health transformations. TBG’s team of more than 80 practitioners and health-system clients (including Johns Hopkins and Penn Medicine) will bolster Valtech’s healthcare and digital experience capabilities.
-
PharmaLegacy Laboratories Acquires San Diego-Based BTS Research
September 16, 2024
Healthcare Services
PharmaLegacy Laboratories has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO), expanding PharmaLegacy's in vitro and in vivo pharmacology and GLP toxicology capabilities. The acquisition gives PharmaLegacy a local presence in San Diego to increase study capacity and support clients across the United States and North America.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.